AbbVie stock (NYSE:ABBV) has exhibited considerable rally potential, having once achieved over a 50% increase in less than two months in 2020. Furthermore, the stock has undergone seven rallies ...

Throughout 2025, AbbVie’s Skyrizi and Johnson & Johnson’s Tremfya were mainstays at the top of the monthly TV drug ad spending rankings. Indeed, since September, they’d taken turns alternating between ...

What if the future of AI wasn’t a screen in your pocket but something as simple as a pen in your hand? The AI GRID explores how OpenAI’s ambitious new AI pen project, codenamed “Gumdrop,” could ...

Envudeucitinib is now one of at least three medicines poised to offer stiff competition to Sotyktu, an oral medication aiming to challenge standard biologics for psoriasis. So far, the drug hasn’t ...